Chemical formula: C₁₆H₁₄F₃N₅O Molecular mass: 349.311 g/mol PubChem compound: 71616
Voriconazole is a triazole antifungal agent. The primary mode of action of voriconazole is the inhibition of fungal cytochrome P450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J02AC03 | Voriconazole | J Antiinfectives for systemic use → J02 Antimycotics for systemic use → J02A Antimycotics for systemic use → J02AC Triazole and tetrazole derivatives |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| VFEND Powder for solution | European Medicines Agency (EU) | MPI, EU: SmPC |
Voriconazole is an active ingredient of these brands:
United States (US)Austria (AT)Canada (CA)Finland (FI)France (FR)Germany (DE)Ireland (IE)Italy (IT)Japan (JP)Malta (MT)Mexico (MX)Netherlands (NL)Nigeria (NG)Poland (PL)Spain (ES)Tunisia (TN)Turkey (TR)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
